Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) ClinicalTrials.gov Identifier : NCT03202303 Recruitment Status : Not yet recruiting First Posted : June 28, 2017 Last Update Posted : April 2, 2019 https://clinicaltrials.gov/ct2/show/NCT03202303?term=cannabinoids&cond=Autism+Spectrum+Disorder&rank=2 Sponsor : Eric Hollander Collaborators : United States Department of Defense, GW Pharmaceuticals Information provided by (Responsible Party) : Eric Hollander, Montefiore Medical Center, USA Study Design Study Type : Interventional  (Clinical Trial) Estimated Enrollment : 100 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Phase 2, 12-week double-blind, randomized, placebo-controlled trial Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Masking Description: Double-Blind Primary Purpose: Treatment Official Title: Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) Estimated Study Start Date : June 2019 Estimated [...]